Modality
Degrader
MOA
PI3Ki
Target
B7-H3
Pathway
DDR
CRC
Development Pipeline
Preclinical
~Jul 2010
→ ~Oct 2011
Phase 1
~Jan 2012
→ ~Apr 2013
Phase 2
~Jul 2013
→ ~Oct 2014
Phase 3
~Jan 2015
→ ~Apr 2016
NDA/BLA
~Jul 2016
→ ~Oct 2017
Approved
Jan 2018
→ Dec 2031
ApprovedCurrent
NCT05881509
2,553 pts·CRC
2018-01→2031-12·Not yet recruiting
2,553 total pts1 indication
CompletedCurrentUpcoming
Catalysts (1)
2031-12-265.7y awayPh3 Readout· CRC
Trial Timeline
2018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2Q3Q4
Approved
Not yet…
Catalysts
Ph3 Readout
2031-12-26 · 5.7y away
CRC
Not yet recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT05881509 | Approved | CRC | Not yet recr... | 2553 | UPCR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| LLY-4358 | Eli Lilly | Phase 3 | B7-H3 | |
| Ceviglumide | Roche | NDA/BLA | B7-H3 | |
| Tiramavacamten | Roche | Preclinical | SGLT2 | |
| NVS-5126 | Novartis | Phase 3 | SHP2 | |
| Voxacilimab | AstraZeneca | Phase 1/2 | GLP-1R | |
| SNY-9600 | Sanofi | NDA/BLA | B7-H3 | |
| SNY-8628 | Sanofi | NDA/BLA | B7-H3 | |
| Capifutibatinib | Sanofi | Approved | PRMT5 | |
| SNY-9073 | Sanofi | Phase 2 | B7-H3 | |
| NVO-7840 | Novo Nordisk | Phase 2/3 | B7-H3 |